Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.

Maturitas - 20 Jun 2008

Biglia N, Mariani L, Ponzone R, Sismondi P

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Contraceptives, Oral, Hormonal
Share to Estrogen Replacement Therapy
Share to Fallopian Tubes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Ovarian Neoplasms

Share to Ovariectomy

Source

Identifiers

PMID: 18472232
DOI: 10.1016/j.maturitas.2008.03.004

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.PMID 18472232Read ↗

BRCA1/2 carriers and endocrine risk modifiers.Semantic proximity Read ↗

Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.Semantic proximity Read ↗

Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?Semantic proximity Read ↗

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.Semantic proximity Read ↗

Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.Semantic proximity Read ↗

Use of systemic hormone therapy in BRCA mutation carriers.Semantic proximity Read ↗

Management problems. BRCA mutation, prophylactic oophorectomy and HRT.Semantic proximity Read ↗

Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.Semantic proximity Read ↗

Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.Semantic proximity Read ↗

Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.